News >

Expert Discusses Developments in Follicular Lymphoma

Caroline Seymour
Published: Monday, Apr 09, 2018

Lori Ann Leslie, MD

Lori Ann Leslie, MD
Combination regimens with low toxicity profiles are being explored in follicular lymphoma, as novel agents seem to have low single-agent activity in early lines of treatment, says Lori Ann Leslie, MD.

on Hematologic Malignancies, Leslie, lymphoma attending, John Theurer Cancer Center, provided expert insight on the latest developments in the field of follicular lymphoma.

OncLive: What is the state of the treatment paradigm in follicular lymphoma? 

Leslie: A 10-year update from the PRIMA study, presented at the 2017 ASH Annual Meeting regarding the role of maintenance rituximab post-chemoimmunotherapy, showed a continued PFS benefit at 10 years. Over half of the patients who received maintenance rituximab versus observation did not require subsequent therapy compared with 35% in the observation arm. There is the use of maintenance rituximab following bendamustine/rituximab (BR) induction therapy. Though there are no clinical trials that are randomized to support this approach, there were some retrospective studies and analyses of prior follicular lymphoma cohorts that suggest a similar PFS benefit.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication